Observes benralizumab use in people with severe eosinophilic asthma in China
Studies benralizumab in people aged 12 and older with severe eosinophilic asthma.
Plain-language title generated from the registry record
Registry title: A Multicentre, Single Arm, Non-interventional, Real-world Study to Assess Demographic Characteristics and Patient Reported Outcomes in Patients With Severe Eosinophilic Asthma Treated With Benralizumab in China
Key facts
- Where
- Anning, Beijing, Binzhou, Changzhou, Fenyang, Guangdong, Guangzhou, Hangzhou, Hefei, Huzhou, Jiaxing, Jinan, Jinhua, Jining, Jiyuan, Kunshan, Linyi, Mianyang, Nanbu, Nanchang, Nanjing, Ningbo, Shanghai, Shanxi, Shenzhen, Shijiazhuang, Suining, Taiyuan, Weifang, Wuhan, Wuxi, Xi'an, Xiamen, Zhangjiagang, Zhengzhou, and Zhenjiang, ChinaSee the 36 sites
Where in China
- AnningAnning, ChinaTaking people
- BeijingBeijing, ChinaTaking people
- BinzhouBinzhou, ChinaTaking people
- ChangzhouChangzhou, ChinaTaking people
- FenyangFenyang, ChinaTaking people
- GuangdongGuangdong, ChinaTaking people
- GuangzhouGuangzhou, ChinaTaking people
- HangzhouHangzhou, ChinaTaking people
- HefeiHefei, ChinaTaking people
- HuzhouHuzhou, ChinaTaking people
- JiaxingJiaxing, ChinaTaking people
- JinanJinan, ChinaTaking people
- JinhuaJinhua, ChinaTaking people
- JiningJining, ChinaTaking people
- JiyuanJiyuan, ChinaTaking people
- KunshanKunshan, ChinaTaking people
- LinyiLinyi, ChinaTaking people
- MianyangMianyang, ChinaTaking people
- NanbuNanbu, ChinaTaking people
- NanchangNanchang, ChinaTaking people
- NanjingNanjing, ChinaTaking people
- NingboNingbo, ChinaTaking people
- ShanghaiShanghai, ChinaTaking people
- ShanxiShanxi, ChinaTaking people
- ShenzhenShenzhen, ChinaTaking people
- ShijiazhuangShijiazhuang, ChinaTaking people
- SuiningSuining, ChinaTaking people
- TaiyuanTaiyuan, ChinaTaking people
- WeifangWeifang, ChinaTaking people
- WuhanWuhan, ChinaTaking people
- WuxiWuxi, ChinaTaking people
- Xi'anXi'an, ChinaTaking people
- XiamenXiamen, ChinaTaking people
- ZhangjiagangZhangjiagang, ChinaTaking people
- ZhengzhouZhengzhou, ChinaTaking people
- ZhenjiangZhenjiang, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT06862206
- Record updated
- 9 November 2026
- Original description
The objective of this study is to collect empirical data that elucidates the clinical profile and therapeutic efficacy of benralizumab among the patients aged 12 years and above, with severe eosinophilic asthma. The study will focus on the early treatment response, treatment outcomes and the change in asthma control of benralizumab therapy in a real-world setting in China. This study will also describe the physician-reported reasons for discontinuation and switching of benralizumab therapy.Read full original descriptionShow less
A Multicentre, Single Arm, Non-interventional, Real-world Study to Assess Demographic Characteristics and Patient Reported Outcomes in Patients With Severe Eosinophilic Asthma Treated With Benralizumab in China
The objective of this study is to collect empirical data that elucidates the clinical profile and therapeutic efficacy of benralizumab among the patients aged 12 years and above, with severe eosinophilic asthma. The study will focus on the early treatment response, treatment outcomes and the change in asthma control of benralizumab therapy in a real-world setting in China. This study will also describe the physician-reported reasons for discontinuation and switching of benralizumab therapy.
Inclusion: Patients are eligible for inclusion only if all of the following criteria are met:; Aged ≥12 years at the time of signing the informed consent form; Patients with severe eosinophilic asthma prescribed with benralizumab at the discretion of the clinician; For the patients who had received benralizumab prior to enrolment, the interval between the Index date and the date of enrolment must <=4 weeks; ACQ-6 score within 7 days prior to index date is required; Patients must have a current prescription for benralizumab with planned initiation of therapy; Participating patients and/or their legally authorized representative must provide signed and dated written informed consent form prior to any study specific procedures.
Exclusion: Known history of allergy or reaction to any component of benralizumab; Malignancy of any kind; Patients should not be enrolled if any of the following exclusion criteria are met:; Patients currently participating in any other interventional clinical trial; Pregnant, breast-feeding or intending to become pregnant during the study period.